Effect of introduction of chondroitin sulfate into polymer-peptide conjugate responding to intracellular signals
- Tetsuro Tomiyama†1,
- Riki Toita†1,
- Jeong-Hun Kang2,
- Haruka Koga1,
- Shujiro Shiosaki1,
- Takeshi Mori1, 3, 4,
- Takuro Niidome1, 3, 4 and
- Yoshiki Katayama1, 3, 4Email author
© Tomiyama et al; licensee Springer. 2011
Received: 29 March 2011
Accepted: 30 September 2011
Published: 30 September 2011
We recently developed a novel tumor-targeted gene delivery system responding to hyperactivated intracellular signals. Polymeric carrier for gene delivery consists of hydrophilic neutral polymer as main chains and cationic peptide substrate for target enzyme as side chains, and was named polymer-peptide conjugate (PPC). Introduction of chondroitin sulfate (CS), which induces receptor-medicated endocytosis, into polymers mainly with a high cationic charge density such as polyethylenimine can increase tumor-targeted gene delivery. In the present study, we examined whether introduction of CS into PPC containing five cationic amino acids can increase gene expression in tumor cells. Size and zeta potential of plasmid DNA (pDNA)/PPC/CS complex were <200 nm and between -10 and -15 mV, respectively. In tumor cell experiments, pDNA/PPC/CS complex showed lower stability and gene regulation, compared with that of pDNA/PPC. Moreover, no difference in gene expression was identified between positive and negative polymer. These results were caused by fast disintegration of pDNA/PPC/CS complexes in the presence of serum. Thus, we suggest that introduction of negatively charged CS into polymers with a low charge density may lead to low stability and gene regulation of complexes.
Tumor-targeted gene delivery is beneficial for increasing therapeutic effects and reducing the desired side effect. These gene delivery systems are mainly based on passive targeting and active targeting methods. Nanoparticles pass through leaky, tortuous, and heterogeneous angiogenic tumor blood vessels and tend to accumulate more in tumors than in normal tissues showing a well-organized and functional structure. This phenomenon is known as the enhanced permeability and retention effect and is noteworthy as the passive targeting method. Moreover, tumor cells exhibit several hyperactivated receptors and cellular signals (protein kinases and proteases) which play key roles on tumor growth and survival and angiogenesis. Gene delivery systems recognizing these hyperactivated receptors or cellular signals are the main active targeting methods .
Recently, our group has proposed a novel drug or gene delivery system responding to cellular signals and developed some gene regulation systems corresponding to the target protein kinases or proteases such as protein kinase A [2–4], caspase , Ikappa-B kinase , human immunodeficiency virus-1 protease , and protein kinase C [8–12]. Carriers for delivery of genes consisted of neutral and hydrophilic polymer as the main chain and disease-specific peptide substrate as side chains; we named polymer-peptide conjugates (PPC). The disease-specific peptide substrates containing positive amino acids can bind anionic genes. Phosphorylation by protein kinases or cleavage by proteases leads to disintegration of PPC/gene complexes and gene expression. Gene delivery systems recognizing hyperactivated cellular signals show efficient disease-targeted gene delivery.
Chondroitin sulfate (CS) is a negatively charged glycosaminoglycan containing two alternating monosaccharides (N-acetylgalactosamine and glucuronic acid). It recognizes a CD44 receptor, which is hyperactivated on several tumor cells [13–15], leading to receptor-medicated endocytosis.
In the present study, we examined whether introduction of CS into pDNA/PPC complex can increase gene expression in tumor cells. Diameter, zeta potential, and stability of plasmid DNA (pDNA)/PPC/CS complexes and their transfection efficiency for tumor cells were elevated.
Results and discussion
PPC consisted of polyacrylamide as the main chain and the peptide substrate as side chains. The content of peptide as the side chains of the polymer was estimated to be 2.9 mol% for the positive polymer [PPC(S)] containing the phosphorylation site serine (FKKQGS FAKKK) and 2.8 mol% for the control negative polymer [PPC(A)] that the serine in the peptide was substituted with alanine (FKKQGA FAKKK) by using an elemental analysis, respectively. Since the peptide substrate has five cationic amino acids (lysine), it can bind to anionic pDNA. After binding PPC with pDNA, CS was introduced into pDNA/PPC complex.
Staining with WST-8 was used to identify cytotoxicity of pDNA/PPC (charge ratio = 1:2) or pDNA/PPC/CS (charge ratio = 1:2:16) complexes toward HepG2 cells. Twenty-four hours after incubation with complexes, the percentage of viable cells was calculated. The assay results revealed that the complexes did not affect cell viability (>90%) (data not shown).
Cationic polymers with a high cationic charge density form stable complexes with gene and show high transfection efficiency but have high cytotoxicity toward cells and agglutination with blood components. Introduction of CS into these polymers can reduce cytotoxicity and agglutination and lead to receptor-mediated gene delivery [16, 17]. However, there are very few evaluation studies for introduction of CS into polymers with a low cationic charge density. Our study suggest that introduction of negatively charged CS into polymers with a low charge density leads to low stability and gene regulation of complexes.
Materials and methods
PPC was synthesized as described previously . Briefly, acrylamide (41.2 mg, 581 μmol) and N-methacryloylpeptide (8.0 mg, 5.9 μmol), from which the methacryloyl group attached to the amino terminus of the peptide, were dissolved in water, degassed with nitrogen for 5 min, and then polymerized using ammonium persulfate (3.9 mg, 17 mmol) and N,N,N',N',-tetramethylethylenediamine (5.1 μl, 34 mmol) as a redox couple at room temperature for 90 min. The synthesized sample was dialyzed against water overnight in a semi-permeable membrane bag with a molecular weight cutoff of 50,000. The dialyzed sample was lyophilized, and a final sample was obtained as a white powder, which was used as the polymer for PPC. The concentration of the peptide was estimated by elemental analysis.
For making pDNA/PPC/CS complex, 20 μl of pDNA (pCMV-luciferase) (0.1 μg/μl) and 20 μl of PPC (640 μM) were mixed for 20 min at room temperature and then incubated further for 20 min after addition of CS (3.98 mM) into pDNA/PPC solution.
Measurements of zeta potential and diameter of complexes
pDNA/PPC/CS complex solution at a charge ratio of 1:2:16 was adjusted to 1 ml by 10 mM HEPES buffer (pH 7.3) or Opti-MEM (Gibco, Invitrogen Co., Grand Island, NY, USA). The zeta potential and diameter of the complexes were determined using a Zetasizer (Malvern Instruments, London, UK) with the He/Ne laser (633 nm) at a detection angle of 173° and a temperature of 25°C.
Agarose gel electrophoresis
pDNA (0.1 μg) and polymers were mixed in 10 μl HEPES buffer (10 mM) at several charge ratios. The formulation of complex was assayed by 1% agarose gel electrophoresis.
Cytotoxicity of complex toward cells
Cell viability was determined using a cell counting kit containing 4-[3-(2-methoxy-4-nitrophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate sodium salt (WST-8) (Dojindo Laboratories, Kumamoto, Japan). HepG2 cells were incubated in the absence or presence of pDNA/PPC (charge ratio = 1:2) or pDNA/PPC/CS complex (charge ratio = 1:2:16) for 24 h in a 96-well plate. The conditioned medium in each well was replaced with 100 μL of fresh medium containing WST-8, and the cells were incubated for a further 2 h, before measurement of the absorbance at 440 nm. The cell viability (percent) was calculated by normalizing the absorbance of treated cells to that of the untreated control cells.
Transfection of complexes into cells
Cells (5 × 104) were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco Invitrogen Co.) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B (all Gibco). The cells were incubated in a humidified atmosphere containing 5% CO2 and 95% air at 37°C for 24 h. After 24 h, the medium was changed to 500 μL of Opti-MEM (Gibco, Invitrogen Co.), and pDNA/PPC (charge ratio = 1:2) and pDNA/PPC/CS (charge ratio = 1:2:16) complexes were added to wells; concentration of pDNA was 2 μg/well. The cells were incubated at 37°C for 6 h. After 6 h, the medium was changed to DMEM, and cells were further incubated for 18 h. The cultured cells were then scraped and lysed in 100 μL of lysis buffer (20 mM Tris-HCl, pH 7.4, 0.05% Triton-X 100, and 2 mM EDTA). After centrifuging the sample at 12,000 × g at 4°C for 10 min, a 10 μL aliquot of the supernatant was used for measuring chemiluminescence in a MiniLumat LB 9506 (EG & G Berthold, Wildbad, Germany) directly after adding 40 μL of the luciferin substrate. The results are presented as relative luminescence units (RLU) per milligram of total protein.
This work was financially supported by a grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.
- Kang JH, Toita R, Katayama Y: Bio and nanotechnological strategies for tumor-targeted gene delivery. Biotechnol Adv 2010, 28: 757–763. 10.1016/j.biotechadv.2010.06.001View ArticleGoogle Scholar
- Katayama Y, Fujii K, Ito E, Skakihara S, Sonoda T, Murata M, Maeda M: Intracellular signal-responsive artificial gene regulation for novel gene delivery. Biomacromolecules 2002, 3: 905–909. 10.1021/bm025532hView ArticleGoogle Scholar
- Oishi J, Kawamura K, Kang JH, Kodama K, Sonoda T, Murata M, Niidome T, Katayama Y: An intracellular kinase signal-responsible gene-carrier for cell specific gene therapy. J Control Release 2006, 110: 431–436. 10.1016/j.jconrel.2005.10.007View ArticleGoogle Scholar
- Oishi J, Ijuin M, Sonoda T, Kang JH, Kawamura K, Mori T, Niidome T, Katayama Y: A protein kinase signal-responsive gene carrier modified RGD peptide. Bioorg Med Chem Lett 2006, 16: 5740–5743. 10.1016/j.bmcl.2006.08.096View ArticleGoogle Scholar
- Kawamura K, Oishi J, Kang JH, Kodama K, Sonoda T, Murata M, Niidome T, Katayama Y: Intracellular signal-responsive gene carrier for cell-specific gene expression. Biomacromolecules 2005, 6: 908–913. 10.1021/bm0493887View ArticleGoogle Scholar
- Asai D, Tsuchiya A, Kang JH, Kawamura K, Oishi J, Mori T, Niidome T, Shoji Y, Nakashima H, Katayama Y: Inflammatory cell-specific transgene expression system responding to Iκ-B kinase beta activation. J Gene Med 2009, 11: 624–632.View ArticleGoogle Scholar
- Asai D, Kuramoto M, Shoji Y, Kang JH, Kodama KB, Kawamura K, Mori T, Miyoshi H, Niidome T, Nakashima H, Katayama Y: Specific transgene expression in HIV-infected cells using protease-cleavable transcription regulator. J Control Release 2010, 141: 52–61. 10.1016/j.jconrel.2009.08.025View ArticleGoogle Scholar
- Kang JH, Asai D, Kim JH, Mori T, Toita R, Tomiyama T, Asami Y, Oishi J, Sato YT, Niidome T, Jun B, Nakashima H, Katayama Y: Design of polymeric carriers for cancer-specific gene targeting: Utilization of abnormal protein kinase Cα activation in cancer cells. J Am Chem Soc 2008, 130: 14906–14907. 10.1021/ja805364sView ArticleGoogle Scholar
- Tomiyama T, Kang JH, Toita R, Niidome T, Katayama Y: Protein kinase Cα polymeric carrier: its application for gene delivery into human cancers. Cancer Sci 2009, 100: 1532–1536. 10.1111/j.1349-7006.2009.01198.xView ArticleGoogle Scholar
- Toita R, Kang JH, Kim JH, Mori T, Niidome T, Jun B, Katayama Y: Protein kinase Cα-specific peptide substrate graft-type copolymer for cancer cell-specific gene regulation systems. J Control Release 2009, 139: 133–139. 10.1016/j.jconrel.2009.06.011View ArticleGoogle Scholar
- Kang JH, Toita R, Tomiyama T, Oishi J, Asai D, Mori T, Niidome T, Katayama Y: Cellular signal-specific peptide substrate is essential for the gene delivery system responding to cellular signals. Bioorg Med Chem Lett 2009, 19: 6082–6086. 10.1016/j.bmcl.2009.09.034View ArticleGoogle Scholar
- Asai D, Kang JH, Toita R, Tsuchiya A, Niidome T, Nakashima H, Katayama Y: Regulation of transgene expression in tumor cells by exploiting endogenous intracellular signals. Nanoscale Res Lett 2009, 4: 229–233. 10.1007/s11671-008-9230-5View ArticleGoogle Scholar
- Rudzki Z, Jothy S: CD44 and adhesion of neoplastic cells. J Clin Pathol: Mol Pathol 1997, 50: 57–71. 10.1136/mp.50.2.57Google Scholar
- Henke CA, Roongta W, Mickelson DJ, Knutson JR, McCarthy JB: CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J Clin Invest 1996, 97: 2541–2552. 10.1172/JCI118702View ArticleGoogle Scholar
- Faassen AE, Mooradian D, Tranquillo RT, Dickinson RB, Letourneau PC, Oegema TR, McCarthy JB: Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-β-stimulated mouse melanoma cell motility and invasive behavior on type 1 collagen. J Cell Sci 1993, 105: 501–511.Google Scholar
- Pathak A, Kumar P, Chuttani K, Jain S, Mishra AK, Vyas SP, Gupta KC: Gene expression, biodistribution, and pharmacoscintigraphic evaluation of chondroitin sulfate-PEI nanoconstructs mediated tumor gene therapy. ACS Nano 2009, 3: 1493–1505. 10.1021/nn900044fView ArticleGoogle Scholar
- Kurosaki T, Kitahara T, Kawakami S, Nishida K, Nakamura J, Teshima M, Nakagawa H, Kodama Y, Sasaki H: The development of a gene vector electrostatically assembled with a polysaccharide capsule. Biomaterials 2009, 30: 4427–4434. 10.1016/j.biomaterials.2009.04.041View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.